SynAgile Corporation, a Wilson, Wyoming-based pharmaceutical company, closed a $10.4m equity funding.
The round was led by affiliates of TAMCAP LLC.
The proceeds will be used to conduct the first-in-human, Phase 2 clinical trial of SynAgile’s DopaFuse™ delivery system.
SynAgile focuses on developing and commercializing transformative therapeutics using its proprietary OraFuse™ oral dosing technology, with an initial focus on treating debilitating motor complications in patients with Parkinson’s disease
The DopaFuse™ delivery system is a non-invasive, continuous, levodopa-carbidopa delivery system for the treatment of motor fluctuations associated with Parkinson’s disease.